This Recent Research Report That Completely Centers Global Ophthalmic Drugs Market Is An In-Depth Analysis Of Propulsive Forces, Business Vendor Industry Threats And Challenges Includes In Worldwide Market.
The Global Ophthalmic Drugs Market Is Estimated To Expand At A CAGR Of 6% Over The Forecast Period Of 2017-2023, Market Research Future (MRFR) In A Detailed Study.
The rise in the number of visually impaired population is increasing in tandem with the rise in geriatric population. Eye diseases such as Retinal Vein Occlusion (RVO), Wet AMD, Myopic Choroidal Neovascularization (mCNV), diabetic retinopathy, and others are on the rise which generates high demand for ophthalmic drugs. Moreover, a rise in the volume of cataract surgeries followed by a high incidence rate of glaucoma and dry eye are among major growth factors for the global ophthalmic drugs market.
Cutting edge research and development activities by pharmaceutical companies to develop drugs which can cater to the huge unmet needs of the population have resulted in innovation in the ophthalmic drugs arena. In recent years, the market has witnessed a substantial rise in the number of US FDA approvals for novel drugs which have further accelerated market growth. Furthermore, a high number of new drugs are already in the pipeline which is expected to fuel the growth of the market over the forecast period.
Offering Free Sample Report @ https://www.marketresearchfuture.com/sample_request/5753
Other factors driving the market growth include huge research funding for ophthalmology, improving regulatory framework, and growing competition among market players. On the other hand, the market growth might be slowed down by the high cost of treatment and diagnosis of ophthalmic diseases, and side effects of available treatment options.
Sun Pharmaceutical Industries Limited, Santen Pharmaceutical Co., Ltd., Shire Plc,Bausch & Lomb Inc., Pfizer Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.,
Genentech, Inc., Valeant Pharmaceuticals International, Inc., Regeneron Pharmaceuticals, Inc., Allergan Plc, Actavis Generics, and others are the notable players in the global ophthalmic drugs market.
February 2019- Bausch + Lomb, a leading eye health company, announced that it had received FDA approval for LOTEMAX SM (loteprednol etabonate ophthalmic gel). The new gel formulation is intended to treat postoperative inflammation and pain following ocular surgery.
The global ophthalmic drugs market has been segmented based on indication, drug class, type of dosage, product, and distribution channel.
By indication, the global ophthalmic drugs market has been segmented into glaucoma, retinal disorders, inflammation/infection, dry eye, allergies, uveitis, and others.
By drug class, the global ophthalmic drugs market has been segmented into antiallergy, anti-inflammatory,anti-VEGF agents, antiglaucoma, and others. The anti-inflammatory segment has been further segmented into nonsteroidal drugs and steroidal drugs.
By type of dosage, the global ophthalmic drugs market has been segmented into eye drops, eye solutions, ointments, capsules and tablets, and gels.
By product, the global ophthalmic drugs market has been segmented into prescription drugs and OTC drugs.
By distribution channel, the global ophthalmic drugs market has been segmented into hospital pharmacies, online pharmacies, drug stores, and others.
Access Report Details @ https://www.marketresearchfuture.com/reports/ophthalmic-drugs-market-5753
By region, the global ophthalmic drugs market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).
The Americas is reigning the global ophthalmic drugs market on account of the high prevalence of eye diseases, high healthcare expenditure and the existence of key players in the region. Plus, the FDA is also approving many ophthalmic drugs in the region which has boosted the growth of the market.
Europe follows the Americas closely and accounts for the second most significant share of the market. R&D funding by the government, growing presence of key players in the region, and improving reimbursement scenario in the region supports the growth of the market.
APAC is likely to emerge as the fastest growing market for ophthalmic drugs. massive patient pool, development of healthcare technology and expansion of the pharmaceutical industry in the region. Increasing healthcare expenditure and improving reimbursement policies are further favoring the growth of the market.
The MEA market is likely to exhibit sluggish growth due to low penetration of healthcare facilities and low healthcare expenditure.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312